Navigation Links
Metformin Outperforms Common Class of Diabetes Drugs in Study
Date:6/24/2012

SUNDAY, June 24 (HealthDay News) -- Three widely used diabetes drugs are associated with a greater risk of death when compared to a popular drug from a different class, metformin, according to a new study.

Researchers analyzed data from nearly 24,000 patients with type 2 diabetes, average age 62, who were treated with one of three drugs called sulfonylureas (glipizide, glyburide, and glimepiride) or with another type of drug called metformin.

Sulfonylureas help decrease blood sugar levels by stimulating the pancreas to produce insulin. Metformin also helps reduce blood sugar levels.

Overall, all three sulfonylureas were associated with a more than 50 percent greater risk of death compared to metformin, according to the study, which was funded by drug company Astra Zeneca.

The researchers also found that, among diabetes patients with heart disease, glipizide was associated with a 41 percent greater risk of death and glyburide was associated with a 38 percent greater risk of death, compared with glimepiride and metformin.

According to one expert not connected to the study, the new data could provide some guidance for patients.

"Patients taking sulfonylureas should be made aware of this increased risk of death and other oral options for glycemic [blood sugar] control should be discussed," said Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City.

The study was to be presented Sunday at The Endocrine Society's annual meeting in Houston.

"We have clearly demonstrated that metformin is associated with a substantial reduction in mortality risk, and, thus, should be the preferred first-line agent, if one has a choice between metformin and a sulfonylurea," said study author Dr. Kevin M. Pantalone, an endocrinologist at Summa Western Reserve Hospital in Cuyahoga Falls, Ohio.

He conducted the study with a team of researchers from Cleveland Clinic.

Another expert said the study may have "enormous clinical implications."

Dr. Minisha Sood, also an endocrinologist at Lenox Hill, said that sulfonylureas may fare worse than metformin because the former might "interfere" with cardiovascular processes that strengthen and protect heart tissue so it becomes more resilient should a cardiac event occur.

"What's interesting about this study is that all three sulfonylureas examined led to increased mortality rates vs. metformin in the entire cohort study, which included patients without coronary artery disease," Sood added. "Does this mean that we shouldn't be prescribing sulfonylureas at all? I think prospective trials are needed to answer that question, so the jury is still out."

Nearly 26 million people in the United States have diabetes, according to the U.S. Centers for Disease Control and Prevention. Many of these patients also have other health problems, including heart disease.

Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about diabetes medicines.

-- Robert Preidt

SOURCES: Spyros Mezitis, M.D., and Minisha Sood, M.D., endocrinologists, Lenox Hill Hospital, New York City; The Endocrine Society, news release, June 24, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
2. Texting in College Classrooms Common, Distracting
3. Recovery from propofol anesthesia may be sped by use of common stimulant
4. Long-term neuropsychological impairment is common in acute lung injury survivors
5. Overuse Injuries Common Among Female College Athletes
6. Common Blood Pressure Drug Safe for Heart Failure: Study
7. Test links strains of common parasite to severe illness in US newborns
8. Common Plastics Chemical Might Boost Diabetes Risk
9. Off-Label Drug Use Appears Common
10. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
11. Slow-growing babies more likely in normal-weight women; Less common in obese pregnancies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Metformin Outperforms Common Class of Diabetes Drugs in Study
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to ... Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed a ... or restricted lighting. As such, it eliminates the need to turn on a light ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
Breaking Medicine Technology: